.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Erhard Seifried

Further involvements

21/09/2022
12:00 – 12:10 6 Min. 4 Min.
Abstractvortrag (Best Abstract)
VS-5-2 (Best Abstract)
Using a mathematical simulation model to predict the impact of changes in platelet concentrate shelf life
2. Versorgungsforschung, 5. Infektionssicherheit von Blutprodukten
22/09/2022
09:10 – 09:20 6 Min. 4 Min.
Abstractvortrag
VS-9-3
Rapid and complete Clearance of HPA-1a mismatched Platelets in a human Model of Fetal and Neonatal Alloimmune Thrombocytopenia by a hyperimmune Plasma derived polyclonal HPA-1a antibody
21. Fetomaternale Inkompatibilität, 7. Immunhämatologie und Immunologische Grundlagen
22/09/2022
13:50 – 14:00 6 Min. 4 Min.
Abstractvortrag
VS-13-3
Long-term Follow up (> 1 year) of Plasma Donors and Patients treated with COVID-19 Convalescent Plasma within the CAPSID trial
19. COVID-19, 9. Hämotherapie
22/09/2022
14:00 – 14:10 6 Min. 4 Min.
Abstractvortrag
VS-13-4
A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathogen: Experience from collection of very high-titer plasma from superimmunized individuals
1. Blutspende und Donormanagement, 19. COVID-19
22/09/2022
16:50 – 16:55 3 Min. 2 Min.
Poster
PS-1-6
Machine learning modelling to precisely predict hemoglobin and iron content in individual packed red blood cell units
18. Zukunftsgebiete der Transfusionsmedizin, 3. Blutkomponenten – Herstellung und Qualitätskontrolle
22/09/2022
17:25 – 17:30 3 Min. 2 Min.
Poster
PS-2-12
Development of a test cell-panel that provides the framework for fast, sensitive and reliable FNAIT-causing HPA antibody detection
21. Fetomaternale Inkompatibilität, 7. Immunhämatologie und Immunologische Grundlagen
22/09/2022
17:25 – 17:30 3 Min. 2 Min.
Poster
PS-1-13
Quality assessment of routine produced mirasol pathogen reduction system treated platelet concentrates
18. Zukunftsgebiete der Transfusionsmedizin, 5. Infektionssicherheit von Blutprodukten
22/09/2022
17:45 – 17:50 3 Min. 2 Min.
Poster
PS-4-18
Human breast milk bank – Frankfurt experience after > 3500 bottles of delivered donor human breast milk
18. Zukunftsgebiete der Transfusionsmedizin, 3. Blutkomponenten – Herstellung und Qualitätskontrolle